GER-009-06-AVX Early Therapy in Multiple Sclerosis (FIT)

Biogen

Status: Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Study type: Observational

Funder types: Industry

Identifiers

NCT00492570

GER-009-06-AVX

Details and patient eligibility

About

This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.

Full description

This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.

Enrollment: 230 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• CIS (according to indication) or early Relapsing Remitting Multiple Sclerosis

Exclusion criteria

• treatment with DMT during the last 12 months